| Bioactivity | BGC-20-1531 (PGN 1531), a benzenesulfonamide derivative, is a selective EP4 antagonist. BGC-20-1531 binds to PGE2 enhancing the ATPase activity, which are coupled to Gs proteins and thus activate adenylate cyclase generating cAMP and activating PKA. BGC-20-1531 is promising for research of liver disorders[1][2]. |
| CAS | 1186532-61-5 |
| Formula | C26H23N2NaO6S |
| Molar Mass | 514.53 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ammazzalorso A, et al. N-acylsulfonamides: Synthetic routes and biological potential in medicinal chemistry. Chem Biol Drug Des. 2017 Dec;90(6):1094-1105. [2]. Hodeify R, et al. PGE2 upregulates the Na+/K+ ATPase in HepG2 cells via EP4 receptors and intracellular calcium. PLoS One. 2021 Jan 14;16(1):e0245400. |
BGC-20-1531
CAS: 1186532-61-5 F: C26H23N2NaO6S W: 514.53
BGC-20-1531 (PGN 1531), a benzenesulfonamide derivative, is a selective EP4 antagonist. BGC-20-1531 binds to PGE2 enhanc
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.